US2013131331A1PendingUtilityA1

Cancer-cell-specific cytostatic agent

Assignee: GENECARE RES INST CO LTDPriority: Nov 19, 2004Filed: Nov 7, 2012Published: May 23, 2013
Est. expiryNov 19, 2024(expired)· nominal 20-yr term from priority
C12N 15/1137C12N 2310/14A61P 35/02A61P 43/00A61P 35/00A61K 31/7088C12N 15/11C12N 15/09
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.

Claims

exact text as granted — not AI-modified
1 . A double-stranded RNA that can suppress the expression of an RecQ1 gene by an RNAi effect, wherein the RNA comprises a structure in which an RNA comprising the nucleotide sequence of SEQ ID NO: 40 and an RNA comprising a sequence complementary to said RNA are hybridized. 
     
     
         2 . The double-stranded RNA of  claim 1 , which comprises a structure in which one or more DNAs or RNAs overhang at an end. 
     
     
         3 . A DNA vector that can express an RNA comprising the nucleotide sequence of SEQ ID NO: 40. 
     
     
         4 . A cancer cell-specific cell proliferation inhibitor which comprises the RNA of  claim 1  or  2 , or the DNA of  claim 3 . 
     
     
         5 . An anticancer agent comprising the cancer cell-specific cell proliferation inhibitor of  claim 4  as an active ingredient.

Join the waitlist — get patent alerts

Track US2013131331A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.